SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
PURSUANT
TO SECTION 13 OR 15(D) OF THE
SECURITIES
EXCHANGE ACT OF 1934
Date
of
Report (Date of earliest event reported): August 27, 2006
IMMUNOTECHNOLOGY
CORPORATION
(Exact
Name of Registrant as Specified in Charter)
|
Delaware
|
|
0-24641
|
|
84-1016435
|
|
(State
or other jurisdiction
of
incorporation)
|
|
(Commission
File
Number)
|
|
(IRS
Employer
Identification
Number)
|
Executive
Pavilion, 90 Grove Street, Ridgefield, Connecticut
06877
(Address
of principal executive offices) (Zip Code)
(203)431-3300
(Registrant’s
telephone number, including area code)
N/A
(Former
Name or Former Address, if Changed Since Last Report)
Check
the
appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following
provisions (see General Instruction A.2. below).
o
Written communications
pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o
Soliciting material pursuant to Rule 14a-12 under the
Exchange Act (17 CFR 240.14a-12)
o
Pre-commencement communications pursuant to Rule
14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o
Pre-commencement communications pursuant to Rule
13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
CAUTIONARY
STATEMENT REGARDING FORWARD LOOKING STATEMENTS
This
report on Form 8-K contains "forward-looking statements" within the meaning
of
Section 27A of the Securities Act of 1933, as amended (the "Securities
Act")
and
Section 21E of the Securities Exchange Act of 1934, as amended (the
"Exchange
Act").
We
intend the forward-looking statements to be covered by the safe harbor
provisions for forward-looking statements in these sections. All statements
regarding our expected financial position, business and financing plans are
forward-looking statements. These statements can sometimes be identified by
our
use of forward-looking words such as "may," "will," "should," "expect,"
"anticipate," "project," "designed," "estimate," "plan" and "continue." Although
we believe that our expectations in such forward-looking statements are
reasonable, we cannot promise that our expectations will turn out to be correct.
These
forward-looking statements are subject to certain risks, uncertainties and
assumptions relating to ImmunoTechnology Corporation. Should one or more of
these risks or uncertainties materialize, or should the assumptions underlying
our forward-looking statements prove incorrect, our future performance and
actual results of operations could vary significantly from those anticipated,
projected, believed, expected, intended or implied. We undertake no obligation
to update any of the forward-looking statements in this Report, which speak
only
as of the date they were made.
Item
5.02 Departure
of Directors or Principal Officers; Election of Directors; Appointment
of Principal Officers
On
August
27, 2006, Stephen Hieber tendered his resignation as Chief Financial Officer
of
ImmunoTechnology Corporation (the “Company”)
effective September 7, 2006, or such later date as needed to assist with the
transition to a new principal financial officer. To the knowledge of the
Company’s executive officers, Mr. Hieber’s resignation was not due to any
disagreement with the Company’s operations, policies or practices.
The
Board
of Directors of the Company has not yet chosen a permanent replacement for
Mr.
Hieber or determined who will act as interim principal financial officer while
the Board of Directors conducts a search for a permanent replacement for Mr.
Hieber.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant
has
duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
|
|
IMMUNOTECHNOLOGY
CORPORATION
|
|
|
|
|
Dated:
August 29, 2006
|
By:
/s/ Stephen M.
Hicks
|
|
|
Stephen
M. Hicks
|
|
|
President
|
|
|
|